患者偏好及其对慢性肝炎B-A综述的影响
Lin Zhang1,2, Yunyue Liu2, Jinping Tian2,3
1Department of Infectious Diseases, The Affiliated Suqian First People's Hospital of Nanjing Medical University, Suqian, Jiangsu Province, People's Republic of China.
Patient preference and adherence
|December 6, 2023
概括
患者的偏好显著影响慢性乙型肝炎 (CHB) 治疗的坚持. 将患者需求纳入CHB管理计划对于有效的长期护理至关重要.
科学领域:
- 肝病学 肝病学是一种肝病学.
- 传染性疾病 传染性疾病
- 以患者为中心的护理
背景情况:
- 慢性乙型肝炎 (CHB) 是一种普遍的病毒感染,需要持续管理.
- 当前的CHB治疗指南往往没有充分纳入患者的偏好.
- 从历史上看,CHB治疗中的医疗决定一直以医生为中心,限制了患者的参与.
研究的目的:
- 探索患者在慢性乙型肝炎治疗中的偏好.
- 阐明患者偏好对CHB治疗坚持的影响.
- 为制定个性化和有效的CHB医疗保健策略提供信息.
主要方法:
- 关于CHB治疗患者偏好的文献综述.
- 分析患者偏好对坚持治疗的影响.
- 综合发现以指导临床实践.
主要成果:
- 患者的偏好直接影响CHB的治疗坚持和结果.
- 忽视患者的偏好可能导致治疗效率低于最佳水平.
- 了解患者的态度,期望和需求至关重要.
结论:
- 尊重患者的偏好对于有效的CHB管理至关重要.
- 整合以患者为中心的方法可以改善治疗坚持和长期结果.
- 需要个性化的CHB护理策略来提高患者的参与度和有效性.
相关概念视频
Hepatic Drug Excretion: Influencing Factors
The biliary system of the liver, crucial for bile secretion and drug excretion, comprises intrahepatic bile ducts that merge to form the common hepatic duct. This duct, carrying hepatic bile, combines with the cystic duct, draining the gallbladder and forming the common bile duct, which empties into the duodenum. Bile, produced by hepatic cells lining the bile canaliculi, is composed primarily of water, bile salts, pigments, electrolytes, and lesser amounts of cholesterol and fatty acids. Bile...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug
In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
Hepatitis
Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...


